Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S95011 in Primary Sjögren's Syndrome
NCT04605978Phase 2Completed
- Sponsor
- Servier
- Start
- Aug 2021
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in primary Sjögren's syndrome comparing Lusvertikimab with Placebo (2 arms). Primary endpoint: EULAR Sjögren's Syndrome Disease Activity Index at 13 weeks. Started Aug 2021; status: completed.
02
Drugs
lusvertikimab
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on NCT04605978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04605978.